Helix BioPharma Corp. (TSE:HBP – Get Free Report) passed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$0.18 and traded as high as C$0.20. Helix BioPharma shares last traded at C$0.20, with a volume of 2,000 shares traded.
Helix BioPharma Stock Performance
The stock has a market cap of C$44.74 million, a P/E ratio of -6.50 and a beta of -0.74. The company has a quick ratio of 1.04, a current ratio of 1.46 and a debt-to-equity ratio of 773.67. The business has a 50 day moving average price of C$0.18 and a two-hundred day moving average price of C$0.20.
About Helix BioPharma
Helix BioPharma Corp. operates as an immune-oncology company in Canada. It is developing L-DOS47 for the treatment of non-small cell lung cancer; and V-DOS47 that targets the vascular epithelial growth factor receptor 2. Helix BioPharma Corp. has collaboration agreements with Moffitt Cancer Center to investigate the pharmacodynamics of L-DOS47 and determine the benefits of combining L-DOS47 with immune checkpoint inhibitors; and with University Hospital Tuebingen to assess the therapeutic response of L-DOS47 in cancer models expressing CEACAM6, with advanced preclinical metabolic imaging.
Read More
- Five stocks we like better than Helix BioPharma
- How Technical Indicators Can Help You Find Oversold Stocks
- High-Yield Texas Instruments Could Hit New Highs Soon
- Overbought Stocks Explained: Should You Trade Them?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- ETF Screener: Uses and Step-by-Step Guide
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Helix BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.